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Abstract 
Food recalls and incidence of foodborne disease are on the rise throughout the world.  
Food products are recalled in the United States almost daily, and typically a large quantity of 
food is affected.  Pathogenic microorganisms are readily invading the food supply and traditional 
methods and use of antimicrobials are not performing as well as in the past.  The microorganisms 
that prompt the recalls cause symptoms ranging from mild gastroenteritis to death.  All humans 
eat food, therefore all humans have the potential to be exposed to pathogens in food at some 
point in their life.  There is a need for new, more effective antimicrobials for use on food 
products in order to ensure that consumers have access to a safe food supply.  Any new 
treatments for prevention of pathogenic growth in the food supply should be researched.  Phage 
preparations used as antimicrobials on food products are a novel idea.  Phages are advantageous 
over traditional antimicrobials such as antibiotics, pesticides, and sanitizers in numerous ways.  
This report presents the history of phage and phage therapy in humans, advantages and 
disadvantages of phage use over traditional methods, current phage preparations available or 
under research, and approvals and objections of phage use in the food supply.   
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Chapter 1: Introduction and History 
Numerous antimicrobial products exist.  Bacteriophages have been found in human 
surroundings for generations, and use of the microorganism to combat bacterial pathogens is a 
constant area of research.  Bacteriophages have the potential to be an effective antimicrobial for 
use on foods, without some of the side effects present in current methods.  Bacteriophage is only 
one of the numerous methods being considered for use as an antimicrobial in foods.  
 
Definition and Mechanism of Action 
Bacteriophage, also known as phage, is a type of virus that infects only bacterial cells.  
Phages are very tiny and measure 20 to 200 nanometers, which is approximately 100 times 
smaller than most bacteria.  Phage comes from the Greek word phagin, which translates “to eat 
or devour” (Sulakvelidze et al. 2001).  Phages are very specific toward their target bacteria; they 
only infect that particular type or strain, and have no effect on any other type of cell including 
human, animal, and plant cells.  Phages are not living organisms but consist simply of genetic 
material wrapped in a protein or membrane outer coating (Snyder and Champness 2003).  
Typically, a phage has a hollow head that contains tightly packed genetic material such as DNA 
or RNA, and a tail with a binding site specific to their target bacteria (Figure 1).  The genetic 
material is forced into the bacterial cell through the tail and new phages are replicated rapidly, 
sometimes as great as 3.3 phages/minute.  A typical DNA phage injects genetic material into the 
cell and RNA transcription commences immediately.  Retroviruses are a type of RNA phage that 
uses reverse transcriptase, an enzyme, to transcribe the RNA into DNA inside the host cell.  
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Other RNA phages use enzymes known as RNA replicases to replicate their RNA and therefore 
do not transcribe to DNA as an intermediate (Snyder and Champness 2003).   
 
 
Figure 1.  A representative schematic of the structure of a bacteriophage. 
 (taken from Intralytix, Inc. 2006a) 
 
Two types of phages exist: virulent (lytic) and temperate (lysogenic).  Virulent phages 
cause lysis of the cell by interrupting the metabolism of the bacteria, which subsequently causes 
rupturing of the cell wall and results in death of the cell (Figure 2).  Lysis begins with the phage 
attaching to the cell wall of the target bacteria and injecting its genetic material.  Once inside the 
bacterium, replication begins and eventually the cell bursts to release the daughter phages and 
the cycle starts over.  Temperate phages will typically integrate their genetic material along with 
that of the host cell to form what is known as a prophage.  Prophages use a process known as 
transduction to transfer the combined bacterial and viral genetic material between host cells.  
Some temperate phages are capable of lysing the cell.  The phage of concern in the area of phage 
therapy and for use as an antimicrobial on food is the lytic phage. 
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Figure 2. Flow diagram of the lytic cycle of a bacteriophage ( ≈ 20 min).  
(taken from EBI Food Safety 2006a) 
 
Bacteriophage Therapy: The Beginning 
In 1896, a British bacteriologist by the name of Ernest Hankin, was the first to report on 
phages when he discovered that sewage water from the Ganges and Jumna rivers in India was an 
effective antimicrobial against cholera, caused by the bacteria Vibrio cholerae (Sulakvelidze et 
al. 2001).  Frederick Twort investigated bacteriophage in 1915, but chose not to fully pursue and 
understand the meaning of his findings.  Felix d‟Herelle also discovered the presence of the 
viruses in 1915 while studying an outbreak of dysentery among French soldiers (Sulakvelidze et 
al. 2001).  During his investigation, one step of the process consisted of plating a mixture 
containing Shigella and fecal samples from the patients onto an agar medium to observe bacterial 
growth.  The cultures on the agar plates showed areas of clearing throughout the bacterial 
growth, and these areas were attributed to the phages.  D‟Herelle termed the clearings “plaques” 
and are still known by that name today (Figure 3).  These clearings are currently used to denote 
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phage growth in laboratory settings.  D‟Herelle is credited with the official discovery of 
bacteriophage in 1917 when his research was presented to the French Academy of Sciences and 
subsequently published. 
 
Figure 3. Lysis plaques of lambda phage on Escherichia coli bacteria. 
(taken from Wikipedia 2007a) 
 
The first clinical studies of phage therapy began in 1919 when d‟Herelle used a phage 
preparation to treat a twelve-year old boy suffering from dysentery.  The success was rapidly 
evident when the boy began to improve within 24 hours after one dose of the phage, and 
completely recovered within a few days.  Subsequently, three more patients suffering from 
dysentery were treated and began to improve within 24 hours after administration of one dose.  
In 1921, Richard Bruynoghe and Joseph Maisin reported successful treatment of staphylococcal 
skin lesions using bacteriophage.  The phage was injected into and around the open skin lesions 
and subsequent improvements in patient conditions were noticed after 24 to 48 hours 
(Sulakvelidze, et al. 2001).   
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Types of Bacteriophage 
In 2005, United States Environmental Protection Agency (US EPA) estimated that 
approximately 1,030 different phages existed throughout the world.  These bacteriophages have 
been characterized into several distinct families  (Table 1).  Understanding the family to which a 
phage belongs can provide valuable information regarding shape, genetic material, and similar 
phages.  A commonly researched phage is T4 of the Myoviridae family; this phage infects E. coli 
bacteria.  T4 phage contains more than 200 genes and its DNA genome is approximately 10μm 
in length (Snyder and Champness 2003).  Nobel Prize winning scientists Max Delbrück, Alfred 
Hershey, Salvador Luria, Francis Crick, and James D. Watson used phage T4 in their research.  
According to Snyder and Champness (2003) an advantage of analyzing T4 replication is that 
rather than using the host cell replication proteins, T4 encodes many of its own including “DNA 
polymerase, sliding clamp, clamp-loading proteins, primase, replicative helicase DNA ligase, 
etc.”  The characterization of phage is especially useful to researchers developing new industrial 
phage products or applying the genetic information to understand the phage mechanism. 
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Table 1. Chart of the twelve distinct groups of bacteriophage 
Family or Group: Genera: Type Member:
Particle 
Morphology: Envelope: Genome:
Corticoviridae Corticovirus PM2 isometric No
supercoiled 
d/s DNA
Cystoviridae Cystovirus Ø6 isometric Yes
3 segments 
d/s RNA
Inovirus coliphage fd
Plectrovirus
Acholeplasma 
phage
Levivirus coliphage MS2
Allolevirus
coliphage 
Qbeta
Lipothrixviridae Lipothrixvirus
Thermoproteus 
phage 1 rod Yes
linear d/s 
DNA
Microvirus
coliphage 
ØX174
Spirovirus
Spiroplasma 
phages
Mac-1 phage
Myoviridae coliphage T4 tailed phage No
linear d/s 
DNA
Plasmaviridae Plasmavirus
Acholeplasma 
phage pleiomorphic Yes
Circular d/s 
DNA
Podoviridae coliphage T7 tailed phage No
linear d/s 
DNA
Siphoviridae
lambda phage 
group
coliphage 
lambda tailed phage No
linear d/s 
DNA
Sulpholobus 
shibatae virus SSV-1 lemon-shaped No
circular d/s 
DNA
Tectiviridae Tectivirus phage PRD1 icosahedral No
linear d/s 
dna
Microviridae
icosahedral No
circular s/s 
DNA
Inoviridae
rod No
circular s/s 
DNA
Leviviridae
icosahedral No
1 (+)strand 
RNA
 
Source: taken from Tulane University 1999 
Phage Production on a Commercial Scale 
 
D‟Herelle had a commercial laboratory in Paris, France that produced five phage 
preparations in the early 1900‟s.  In the United States, Eli Lilly produced seven phage 
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preparations during the 1940‟s.  However, once mass production of penicillin began in the 
1940‟s, the focus of the medical field shifted from phage therapy to antibiotic therapy.  The high, 
exclusive usage of antibiotics contributed to the drug resistant bacteria of today.   
Currently, several companies conducting phage research exist throughout the world.  The 
most well-known phage therapy research and treatment center is the Phage Therapy Center 
located in Tbilisi, Republic of Georgia in the former Soviet Union.  Phage research has been 
ongoing in Republic of Georgia for over 80 years. Currently the Phage Therapy Center (2005) 
can provide phages against many gram-positive bacteria including Staphylococcus spp. such as 
Methicillin Resistant Staphylococcus aureus (MRSA), Streptococcus spp., Pseudomonas 
aeruginosa, Enterococcus spp., and numerous gram-negative bacteria such as Proteus, E. coli, 
and Klebsiella pneumoniae.  The focus of the Phage Therapy Center is primarily on patients 
dealing with an infection that is chronic, located in an area with poor circulation, or caused by a 
bacterium that is antibiotic resistant.  Phage International Inc. is located in California, United 
States and was merged with Phage Therapy Center in 2005. 
GangaGen, Inc. (2007) is a biotechnology company based in India that is currently 
researching phage therapy in the areas or recurring urinary tract infections and prophylactic 
therapy for patients entering a hospital setting.  Biophage Pharma, Inc. (2006) is a 
biopharmaceutical company in Canada that is developing therapeutic and diagnostic phage-based 
products.  Several other companies, primarily in the United States, are focusing their phage 
research on food products in order to prevent food-borne illness prior to infection of the victim. 
Benefits of Phage Use 
Numerous benefits of phages over antibiotics exist.  Notable examples include killing of 
the target bacteria, whereas antibiotics sometimes only inhibit growth; very specific to target 
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bacteria so no adverse effects on beneficial microflora; lower risk of bacteria mutating to resist 
the phage (Table 2).  According to Phage Biotech Ltd (2007), the cost of producing phage is low.   
Table 2. Side-by-side comparison of the prophylactic and/or therapeutic uses of phages and antibiotics.  
 
Bacteriophages Antibiotics Comments  
Very specific (i.e., usually 
affect only the targeted 
bacterial species); therefore, 
dysbiosis and chances of 
developing secondary 
infections are avoided. 
Antibiotics target both 
pathogenic microorganisms 
and normal microflora. This 
affects the microbial balance 
in the patient, which may lead 
to serious secondary 
infections. 
High specificity may be considered to be 
a disadvantage of phages because the 
disease-causing bacterium must be 
identified before phage therapy can be 
successfully initiated. Antibiotics have a 
higher probability of being effective than 
phages when the identity of the etiologic 
agent has not been determined.  
Replicate at the site of 
infection and are thus 
available where they are 
most needed . 
They are metabolized and 
eliminated from the body and 
do not necessarily 
concentrate at the site of 
infection. 
The “exponential growth” of phages at 
the site of infection may require less 
frequent phage administration in order to 
achieve the optimal therapeutic effect.  
No serious side effects have 
been described. 
Multiple side effects, 
including intestinal disorders, 
allergies, and secondary 
infections (e.g., yeast 
infections) have been 
reported. 
A few minor side effects reported for 
therapeutic phages may have been due 
to the liberation of endotoxins from 
bacteria lysed in vivo by the phages. 
Such effects also may be observed when 
antibiotics are used.  
Phage-resistant bacteria 
remain susceptible to other 
phages having a similar 
target range. 
Resistance to antibiotics is 
not limited to targeted 
bacteria. 
Because of their more broad-spectrum 
activity, antibiotics select for many 
resistant bacterial species, not just for 
resistant mutants of the targeted bacteria.  
Selecting new phages (e.g., 
against phage-resistant 
bacteria) is a relatively rapid 
process that can frequently 
be accomplished in days or 
weeks. 
Developing a new antibiotic 
(e.g., against antibiotic-
resistant bacteria) is a time-
consuming process and may 
take several years. 
Evolutionary arguments support the idea 
that active phages can be selected 
against every antibiotic-resistant or 
phage-resistant bacterium by the ever-
ongoing process of natural selection. 
 
Source: taken from Sulakvelidze 2001 
 
Phages have an increased capability of killing bacteria that has become antibiotic 
resistant.  Phages are beneficial over anti-microbial sanitizers because they target only one 
bacterium as opposed to a wide spectrum of bacteria.  Traditional anti-microbial sanitizers tend 
to kill all bacteria exposed to them, and in turn bacteria mutate and build resistance to the 
sanitizer. 
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Safety 
Phages are ubiquitous in the environment and may be found in soil, water, and food, 
making contact with these microorganisms inevitable.  Bergh et al. (1989) determined 
concentration of phages to be up to 2.5 x 10
8
 plaque forming units (pfu)/ml of natural unpolluted 
water.  Research shows that the majority of known viruses do not have the ability to penetrate 
human tissues and cause disease (Omnilytics 2006).  A historical study conducted by Whitman 
and Marshall (1971) proved that phages are found in refrigerated food products.  Quantities and 
types of food products containing phage included:  
 11 of 17 total samples of ground beef  
 4 of 7 samples of pork sausage 
 4 of 8 samples of chicken 
 2 of 5 samples of raw milk 
According to the USEPA (2005) in the Federal Register, as many as 1.4 x 10
6
 pfu/g of 
the phage that targets Propionibacterium freundenreichii has been found in Swiss cheese. 
Research conducted by Bruttin and Brussow (2005) at Nestle showed the apparent safety 
of oral administration of E. coli phage T4.  Fifteen adult volunteers participated in a blind study 
and were given a low dose (10
3
 pfu/ml), a high dose (10
5
 pfu/ml), and a placebo in alternating 
sequences.  The doses were administered in drinking water and no serious adverse effects were 
noted.   
Danisco is a worldwide company that provides cultures for use in meat and yogurt 
products.  Currently they are conducting research to determine how to control phages that are 
killing their cultures and resulting in reduced yields (Danisco 2007).  In March 2007, a 
breakthrough was announced in which scientists at Danisco found the genomic avenue to 
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promote phage resistance in bacterial cultures.  Therefore, consumers are already exposed to 
“good” bacteria and phages through products that utilize cultures.  
Phage could possibly have an adverse effect on humans if used to treat a bacterium that 
contains toxin, since lysing of the cell would release the toxin.  This scenario could occur during 
phage preparation using a bacterium that produces toxin, if any residue of the bacteria remained 
in the phage preparation. 
 
Chapter 2: Common Food Pathogens 
 
Bacteria are ubiquitous in the environment and all living things come into contact with 
these microorganisms daily.  Pathogenic bacteria cause diseases in humans and plants, and 
directly affect the supply and quality of the food chain.  There has been an increase in food-borne 
disease outbreaks in recent years.  The majority of these outbreaks can be contributed to a select 
few pathogenic bacteria that will be discussed in this chapter. 
Food-borne Human Pathogens 
 
Numerous bacteria cause food-borne illnesses throughout the world every year.  In the 
United States the Centers for Disease Control and Prevention (CDC) annually tracks reports of 
all outbreaks, their sources, bacteria involved, and states affected (Table 3).  CDC defines an 
outbreak as “occurrence of two or more cases of a similar illness resulting from the ingestion of a 
common food” (MMWR 2006).  In Europe the European Commission (EC) tracks food-borne 
outbreaks. 
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Table 3. Chart showing the number of reported bacterial food-borne disease  
outbreaks, cases, and deaths in the United States from 1998-2002 
Etiology Outbreaks Cases Deaths
Bacillus cereus 37 571 0
Brucella 1 4 0
Campylobacter 61 1440 0
Clostridium botulinum 12 52 1
Clostridium perfringens 130 6724 4
Escherichia coli 140 4854 4
Listeria monocytogenes 11 256 38
Salmonella 585 16821 20
Shigella 67 3677 1
Staphylococcus aureus 101 2766 2
Streptococcus 1 4 0
Vibrio cholerae 3 12 0
Vibrio parahemolyticus 25 613 0
Yersinia enterocolitica 8 87 0
Total 1182 37881 70
Source: adapted from MMWR 2006  
 
CDC (2005a) declared that known pathogens account for 14 million illnesses, 60,000 
hospitalizations, and 1800 deaths each year in the United States.  The estimation of illnesses, 
hospitalizations, and deaths due to unknown pathogens or unreported cases is five times higher.  
Victim costs associated with food-borne outbreaks include hospitalization and other medical 
costs, lost wages from time off work, and psychological and physical harm.  Estimated costs due 
to salmonellosis alone in the United States approaches $1 billion/year in lost wages and medical 
expenses (CDC 2005a).   
According to Hartford (2002), company costs associated with recalls involving 
pathogenic organisms include: 
 Product Disposition: Removing, returning and disposing of affected 
product 
 Victim lawsuits 
 12 
 Employees redirected to help with investigation and procedures 
regarding recall – costs may result from overtime of current 
employees or outsourcing 
 Loss of consumer trust in product 
 Damage to company image 
 Possible closing of facility if unable to handle financial burden of 
recall 
 
Listeria monocytogenes 
 
Listeria spp. is a group of gram-positive bacilli that exist in the environment (Figure 4).  
Listeria monocytogenes is the most common strain associated with food-borne illness.   
Listeria monocytogenes is an opportunistic pathogen that has the ability to colonize the human 
gastrointestinal system and cause listeriosis.  Symptoms of listeriosis may consist of nausea, 
diarrhea, fever, and/or muscle aches.  Listeria monocytogenes is notorious for infecting pregnant 
women, which subsequently infects the fetus and frequently results in stillbirth or miscarriage.  
Immuno-compromised individuals, the elderly, and young children are susceptible to listeriosis.  
Ingestion of contaminated food is the most likely cause of infection with L. monocytogenes.  
Listeria is a psychrotrophic organism therefore easily killed at high temperatures such as 160
o
F, 
but able to grow well at lower climates including refrigeration temperatures.  Therefore, 
contaminated food typically results from unsanitary conditions during handling of food after it 
has been heat processed.  
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Figure 4. Microscopic image of a Listeria bacterium. 
(taken from Lancaster City Council 2005) 
 
Due to the relatively high fatality rate associated with L. monocytogenes, the two United 
States food regulatory agencies, United States Department of Agriculture‟s Food Safety and 
Inspection Service (USDA-FSIS) and Food and Drug Administration (FDA), have imposed a 
zero tolerance limit for L. monocytogenes in Ready-to-Eat (RTE) food products.  Zero tolerance 
means that this pathogen cannot be found at detectable limits in a food. 
 Foods that are commonly contaminated with L. monocytogenes include meat and dairy 
products such as sliced deli meats and soft cheeses.  CDC (2005b) estimates 2,500 people 
contract a serious form of listeriosis each year in the United States alone and of these, 
approximately 500 will die.  Recent cases of Listeria related USDA-FSIS (2007a) recalls 
include: 
 2,768 pounds of RTE chicken from a Tennessee facility on June 29, 
2007 
 6,907 pounds of RTE turkey products from Diestel Turkey Ranch in 
California on May 1, 2007 
 2.8 million pounds of Oscar Mayer and Louis Rich chicken 
products from Carolina Culinary Foods in South Carolina on 
February 28, 2007.  
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Recent USFDA (2007a) recalls involving Listeria include one initiated on June 19, 2007 
for one lot of diced yellow onions produced by Gills Onions, LLC in California.  The product 
was distributed to six states, and no illnesses were reported as a result of this recall.  Raw milk is 
frequently associated with recalls due to Listeria monocytogenes.  In the first half of 2007, three 
cases of recalled raw milk from three separate dairies were reported (USFDA 2007b). 
Europe has its own recalls and cases of listeriosis that are of concern (Table 4).  The Commission 
Regulation of the European Communities has established microbiological criteria guidelines for  
Table 4. Chart of the observed cases of listeriosis by European country in recent years. 
Country Year Observed Cases
Austria 2000 14
1999 26
Belgium 2000 48
2000 6
Denmark 2001 38
2000 81
England and Wales 2001 144
Finland 2001 29
2000 148
France 2001 187
Germany 2001 220
Greece 2001 3
Iceland 2001 0
Ireland 2001 6
1999 40
Italy 2001 31
2000 26
Netherlands 2001 17
2000 11
Norway 2001 17
Scotland 2001 15
Spain 2000 60
Sweden 2001 67
Switzerland 2000 54
Source: adapted from de Valk et al. 2005  
food products in Europe (Eur-Lex 2005).  Regarding L. monocytogenes, the limits vary 
depending upon the type of food tested.  For RTE foods intended for use by infants or for 
medical purposes, there is a zero tolerance level.  For foods that are able to support growth of L. 
monocytogenes, there is a zero tolerance level unless the manufacturer can prove to the 
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regulatory agency that the product can maintain a level of 100 cfu/g or less throughout the entire 
shelf life of the product.  For food products that do not readily support growth of L. 
monocytogenes, the tolerance limit is less than 100 cfu/g. 
Escherichia coli O157:H7 
 
Escherichia coli are a group of gram-negative enteric bacteria that are commonly found 
in animals (Figure 5).  Some strains exist as normal microflora of the human bowel, but others 
produce toxins resulting in serious infections.  E. coli O157:H7 is an enterohemorrhagic E. coli 
(EHEC) that produces a toxin that can cause bloody diarrhea and severe dehydration in humans.  
According to O‟Flynn et al. (2004) infections with E. coli O157:H7 may be caused by as few as 
10 cells.  If the infection is severe enough, E. coli O157:H7 causes damage to the kidneys and 
leads to hemolytic-uremic syndrome (HUS), which is most common in young children, and may 
result in death.  Foods commonly associated with E. coli O157:H7 contamination include raw or 
undercooked ground beef, raw milk, and most recently, fresh produce.  Cooking meat to 
recommended temperatures and complete pasteurization of milk are effective means to kill  
E. coli O157:H7.  The most famous report of E. coli O157:H7 contamination in food was related 
to ground beef used in hamburgers at Jack-in-the-Box in 1993.  The contaminated hamburgers in 
question were not cooked to a temperature sufficient to kill E. coli O157:H7.  The outbreak 
prompted an increase in testing for E. coli O157:H7 at USDA inspected meat establishments, as 
well as raising awareness of the need to cook ground meat to appropriate temperatures at food 
service establishments and in the home. 
 16 
 
Figure 5. Microscopic image of Escherichia coli O157:H7. 
(taken from Goshen College 2005) 
 
An outbreak of E. coli O157:H7 associated with Natural Selections baby spinach in fall 
of 2006 resulted in 205 confirmed infections and three deaths (USFDA 2007c).  Recent cases of 
USDA-FSIS (2007a) recalls involving E. coli O157:H7 contaminated products include: 
 40,440 pounds of ground beef from a Tyson plant in Texas on  
June 8, 2007 
 26,669 pounds of ground beef from Abbot Meats in Michigan on 
July 21, 2007 
 5,920 pounds of ground beef and buffalo from Nebraska based 
Custom Pack, Inc. on July 25, 2007  
 21.7 million pounds of frozen ground beef patties from Topps Meat 
Company, LLC in New Jersey; initial recall on September 25, 2007 
was expanded on September 29, 2007 (USDA-FSIS 2007b). 
 
One recall that gained an abundance of media coverage involved Taco Bell restaurants in 
the northeastern United States in 2006.  CDC (2006a) believed this case was linked to the lettuce 
used in the restaurants, and caused illnesses in 71 individuals, of which eight developed HUS.  
The recent Topps Meat recall was the second largest beef recall in United States history, and 25 
illnesses were reported in eight states according to the FSIS Recall Release (USDA-FSIS 2007b).  
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The massive recall forced the company to permanently close its doors six days after the recall 
was expanded (Gold 2007).   
In Europe, the EC monitors verocytotoxigenic E. coli (VTEC) that includes E. coli O157.  
EC has defined several key areas of foods where VTEC poses a particular threat to human health 
including “raw or undercooked beef and possibly meat from other ruminants; minced and/or 
fermented beef, and products thereof; raw milk and raw milk products; fresh produce, in 
particular sprouted seeds, and unpasteurised fruit and vegetable juices, and water” (EC 2003a).  
Currently, the EC (2003a) does not recommend any appropriate set of microbiological levels for 
VTEC O157 in foods. 
 
Salmonella 
 
Salmonella spp. is a group of gram-negative enteric bacteria commonly found in animals 
(Figure 6).  Salmonella is typically not part of the normal human flora so presence in humans is 
usually indication of an infection.  Certain individuals are carriers of Salmonella, which means 
they do not get sick from the bacteria but they can transmit the bacteria to other people and cause 
illness.  Gastroenteritis, including diarrhea, fever, and abdominal cramps, is a common symptom 
of infection resulting from ingestion of contaminated foods such as poultry or dairy products.  
Salmonella is easily killed by cooking food to proper temperatures and pasteurizing milk.  
According to the CDC (2006b), approximately 40,000 cases of Salmonella are reported every 
year in the United States.  This number includes only the reported cases, though the actual 
amount of cases including minor, unreported cases might be much higher.  According to the EC 
(2003b), there were 150,165 cases of human salmonellosis in 17 European regions in the year 
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2000.  According to the Commission Regulation of the European Communities microbiological 
criterion on Salmonella, there is a zero tolerance level across all types of foods (Eur-Lex 2005). 
 
Figure 6. Microscopic image of a Salmonella bacterium. 
(taken from Utah Department of Health 2006) 
One recent outbreak of Salmonella resulted from peanut butter distributed throughout the 
United States (USFDA 2007d).  ConAgra, a major worldwide food manufacturer, produced the 
peanut butter under the brand names Peter Pan and Great Value.  As of March 7, 2007, CDC had 
received reports of 425 cases of Salmonella infections, involving 44 states, caused by the 
affected peanut butter.  On June 28, 2007, FDA reported that Veggie Booty snacks made by 
Robert‟s American Gourmet in New York were being recalled due to Salmonella contamination.  
CDC (2007) identified 60 individuals who became sick associated with this product.  People 
from 19 states were affected and most of the victims were young children.  In the first half of 
2007, one case of recalled raw milk was associated with Salmonella contamination (USFDA 
2007b).  Major European countries reported numerous cases in recent years; the EC summarized 
the major outbreaks in 2003 (Table 5).  
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Table 5. Chart of the major foodborne outbreaks of human salmonellosis by food, year, countries affected, 
serotype, and cases. 
Vehicle Year Exporting Country Importing Country Serotype Cases Deaths
Chocolate 1973 Canada USA Salmonella Eastbourne 122 0
1982 Italy UK Salmonella Napoli 245 0
1985-86 Belgium Canada Salmonella Nima 29 0
1987 Norway Finland Salmonella Typhimurium 12 0
Alfalfa Sprouts 1994 Australia Finland & Sweden Salmonella Bovismorbificans 492 0
1995 Netherlands USA & Finland Salmonella Stanley >230 0
1995-96 Netherlands Canada & USA Salmonella Newport 150 0
Black Pepper 1982 Brazil Norway Salmonella Oranienburg 126 1
Pate 1984 France UK Salmonella Gold-coast 506 0
Aspic Glaze 1984 UK International Salmonella Enteritidis PT4 766 2
Mung Bean Sprouts 1988 Australia England Salmonella Saint-paul 143 0
Mustard Cress 1989 Netherlands England Salmonella Gold-coast 14 0
Cantaloupe 1989-90 Mexico USA Salmonella Chester >245 2
Infant Milk Formula 1996 France UK Salmonella Anatum >12 0
Source: taken from EC 2003b
 
Campylobacter jejuni 
 
Campylobacter jejuni is a gram-negative bacterium that causes diarrhea in humans 
(Figure 7).  CDC (2005c) estimates 2.4 million individuals are infected each year in the United 
States, of which approximately 124 cases result in death of the victim.  C. jejuni causes an 
infection known as campylobacteriosis, which is the most common cause of diarrhea due to 
bacterial infection in the United States (USDA-FSIS 2006a).  Campylobacter infections can be 
caused by as few as 400-500 cells (Hagens and Loessner 2007).  Campylobacter jejuni is found 
as part of the normal flora in most live chickens and therefore can be found in an estimated 20-
100% of raw poultry available in retail (USFDA-CFSAN 1992).   
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Figure 7. Microscopic image of Campylobacter jejuni. 
(taken from National Research Council Canada 2005) 
 
In the United States, C. jejuni is not normally associated with outbreaks and infections 
are usually sporadic, however a small amount of outbreaks have been reported due to drinking of 
non-chlorinated water and raw milk.  One Campylobacter related outbreak was reported among 
school children in the United States in 1986.  USFDA-CFSAN (1992) reported that the company 
supplying the milk was not using proper time and temperature requirements to pasteurize the 
milk.  Most infections associated with these bacteria can be avoided with proper cooking of meat 
and poultry, or pasteurization of milk.  
According to USFDA-CFSAN (2001a), pasteurization of milk consists of several 
methods:  
 High-Temperature-Short-Time (HTST): heat at 161oF (72oC) for 15 
seconds 
 Low-Temperature-Long-Time (LTLT): heat at 145oF (63oC) for 30 
minutes 
 Ultra-High-Temperature (UHT): heat at 230oF (138oC) for a 
minimum of 2 seconds; this extends the refrigerated shelf life 60-90 
days 
 Ultrapasteurization: heating at 280-302oF (138-150oC) for 1 to 2 
seconds; if the milk is then hermetically sealed in a sterile package, 
this extends the shelf life to unrefrigerated for 90 days. 
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The EC reported approximately 156,232 cases of human campylobacteriosis in 13 
member states in the year 2001, though the actual number of cases is estimated to be from 8-10 
times higher (European Food Safety Authority 2005). 
 
Plant Crop Pathogens 
 
Several plant pathogens harm crops and cause serious financial trouble to farmers.  
University of Georgia (1998) reported, “crop disease cost Georgia farmers more than 
$654 million, or about 20 percent of the $3.25 billion total crop value” in 1997.  Though these 
bacteria may not be directly harmful to humans as a pathogen, they affect the quality and cost of 
food in the human food chain.   
 
Xanthomonas campestris pv. vesicatoria 
 
 Xanthomonas campestris pv. vesicatoria (Xcv) causes bacterial spot in tomatoes and 
pepper plants (Figure 8).  Bacterial spot was first noticed in Texas in 1912 and is now 
widespread throughout the North and South America, Europe, Asia, and Africa (University of 
Connecticut 1999).  Xcv is easily spread and causes water-soaked, circular, brown spots on the 
leaves of the plants (University of Massachusetts Amherst 2005a).  Seeds are a primary source of 
dispersal of Xcv, and prime conditions for growth of the bacteria include rainfall and 
temperatures between 80-90
o
F.  Current treatment recommendations include buying certified 
seed, rotating fields, and use of chemicals or pesticides.  However, pesticides are typically 
ineffective against Xcv if a significant amount of disease is present. 
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Figure 8. Effects of Xanthomonas-causing bacterial spot on pepper fruits and leaves. 
(taken from University of Massachusetts Amherst 2007) 
 
Pseudomonas syringae pv. tomato 
 
Psuedomonas is a species of bacteria that are gram negative.  Psuedomonas syringae is 
pathogenic to numerous plants and their fruits.  Pseudomonas syringae pv. tomato causes 
bacterial speck on tomato fruits.  Bacterial speck was first noted in Taiwan in 1929 and in the 
United States in 1933 (University of Connecticut 1999).  Optimum growth conditions for this 
bacteria include low temperatures of 64-75
o
F and high moisture environments (University of 
Connecticut 1999).  The bacterium causes small, dark spots or specks on the tissue of the fruit 
(University of Massachusetts Amherst 2005b).  Current treatment recommendations include use 
of disease-free seeds and chemicals or pesticides.  However, pesticides are typically ineffective 
against Pseudomonas. 
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Chapter 3: Current Methods for Control of Bacteria in Food 
 
 Sanitizers, lethality treatments, and pesticides are common tools currently used to combat 
pathogens in the food industry.  Each method is regulated by government agencies FDA, USDA, 
and/or EPA for compliance in areas of concentration, exposure time, and toxicity.  This chapter 
will discuss use of these current methods as antimicrobials on food products and equipment in 
the food industry.  
 
 
Sanitizers 
 
 Numerous sanitizers are used in production facilities to prevent and control pathogenic 
bacteria.  Quaternary ammonium (quat) is a commonly used chemical that is approved for usage 
in food production facilities (Figure 9).  Quat is a cationic surface acting agent commonly used 
as a microbial sanitizer.  Quat acts on the cell membrane of bacteria, and causes loss of structural 
organization of the target cell (McDonnell and Russell 1999).   One example of a liquid quat 
sanitizer is Saniwise Six, manufactured by Supply Systems for use in USDA inspected 
establishments.  Saniwise Six contains the four active ammonium ingredients octyl decyl 
dimethyl ammonium chloride, didecyl dimethyl ammonium chloride, dioctyl dimethyl 
ammonium chloride and alkyl dimethyl benzyl ammonium chloride, hence the term “quaternary 
ammonium” (Supply Systems 2003a).  At strength of 200 ppm exposure for 60 seconds, Supply 
Systems (2003a) claims Saniwise Six eliminates 99.999% of bacteria such as C. jejuni, E. coli 
O157:H7, L. monocytogenes, and various Salmonella species, among other pathogens.  Quat 
compounds may cause eye and skin irritation upon contact and are harmful if swallowed (Supply 
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Systems 2003b).  USDA-FSIS (2006b) claims quat, chlorine compounds, and compounds 
containing periacetic acid are most effective against L. monocytogenes.  USDA-FSIS requires all 
sanitizers used in federally inspected meat facilities be food-grade and approved by FDA.  FDA 
defines sanitizers as “chemical or physical agents that reduce microorganism contamination 
levels present on inanimate environmental surfaces” (USFDA-CFSAN 2001b).  According to 
FDA, sanitizers are for use on inanimate objects that indirectly touch food, and not for use on the 
actual food itself.  Therefore, the equipment will not contaminate the food.  FDA details 
approved sanitizer solutions and concentrations in 21 CFR 178.1010 (US Government Printing 
Office 2000).  USDA requires federally inspected establishments to have procedures for sanitizer 
use on file. These are known as Sanitation Standard Operating Procedures (SSOPs). 
Establishments are also required to keep records of all sanitizers used and strengths.  Often, 
sanitizers must be rotated on a regular basis to discourage bacterial resistance. 
 
Figure 9. Diagram of a quaternary ammonium 
ion in which R represents alkyl groups.  
(taken from Wikipedia 2007b) 
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Lethality Treatments 
 
 USDA has strict guidelines that its federally inspected establishments are required to 
follow in meat preparation.  Requirements include combinations of time and temperature 
depending upon the type of meat (beef, pork, or poultry) and the type of finished product (Table 
6).  USDA requires inspected establishments to have a validated Hazard Analysis and Critical 
Control Point (HACCP) plan in effect that addresses cooking time and temperature requirements 
and keep records that show proof of those requirements being met.  USDA has established 
guidelines for consumers when handling and cooking raw products, though a large majority of 
the population is still unaware of correct handling techniques for raw meat and vegetables, as 
well as cooking times and temperatures. USDA-FSIS (2006c) recommends consumers wash 
hands often when preparing foods, keep foods separate to prevent cross-contamination, cook 
foods to proper internal temperatures, and chill the food immediately.   
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Table 6. Processing temperatures for meeting USDA lethality performance standards for meat products. 
 
          Minimum Internal           Minimum processing time in 
Temperature                minutes or seconds after 
                                               minimum temperature is reached 
              
        Degrees        Degrees          6.5-log10         7-log10 
        Fahrenheit     Centigrade      Lethality        Lethality 
         130             54.4          112 min.       121 min. 
         131             55.0               89 min.        97 min. 
         132             55.6              71 min.        77 min.    
         133             56.1              56 min.        62 min. 
         134             56.7              45 min.        47 min. 
         135             57.2              36 min.         37 min. 
         136             57.8              28 min.         32 min. 
         137             58.4              23 min.         24 min. 
         138             58.9              18 min.         19 min. 
         139             59.5              15 min.         15 min. 
         140             60.0              12 min.         12 min. 
         141             60.6                9 min.         10 min. 
         142             61.1                8 min.           8 min. 
         143             61.7                6 min.           6 min. 
         144             62.2                5 min.           5 min. 
         145             62.8                4 min.*         4 min.* 
         146             63.3            169 sec.         182 sec. 
         147             63.9            134 sec.         144 sec. 
         148             64.4            107 sec.         115 sec. 
         149             65.0              85 sec.           91 sec. 
         150             65.6              67 sec.           72 sec. 
         151             66.1             54 sec.            58 sec. 
         152             66.7             43 sec.            46 sec. 
         153             67.2             34 sec.            37 sec. 
         154             67.8             27 sec.            29 sec. 
         155             68.3             22 sec.            23 sec. 
         156             68.9             17 sec.            19 sec. 
         157             69.4             14 sec.            15 sec. 
         158             70.0              0 sec.**           0 sec.** 
         159            70.6              0 sec.**           0 sec.** 
       160             71.1              0 sec **           0 sec.**  
* Past regulations have listed the minimum processing time for roast beef cooked to 145°F as "Instantly." However, due to their 
large size, most of these roasts dwell at 145°F, or even at higher temperatures, for at least 4 minutes after the minimum internal 
temperature is reached. FSIS has revised this time/temperature table to reflect this and emphasizes that, to better ensure 
compliance with the performance standard, establishments should ensure a dwell time of at least 4 minutes if 145°F is the minimum 
internal temperature employed.  
**The required lethalities are achieved instantly when the internal temperature of a cooked meat product reaches 158°F or above. 
(Source: taken from USDA-FSIS Appendix A 1999) 
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Pesticides 
Pesticides are defined by EPA (2007a) as “substance or mixture of substances intended for:  
 preventing,  
 destroying,  
 repelling, or  
 mitigating any pest” 
to include insecticides, herbicides, fungicides, and any other product that controls pests.   
Pesticides are typically used on crops and EPA regulates use of pesticides in the United States.  
In 2006, EPA implemented a new program known as registration review, to ensure review of a 
pesticide‟s active ingredients every 15 years (EPA 2007b).  EPA has other programs in place 
including re-registration, tolerance reassessment, and special review.  EPA is very strict in their 
testing requirements for a pesticide to become approved for use.  Key areas tested include 
hazards to humans and domestic animals, environmental toxicity, residues, and accumulation 
studies, as well as product performance studies to assess effectiveness (EPA 2007c).  Once 
approved, levels are tightly regulated and enforced to ensure that guidelines are met and toxicity 
to animals, humans, or the environment is kept at a minimum.  According to Iowa State 
University (2003) pesticides have advantages and disadvantages.   
Advantages include: 
 effective against a broad range of pests 
 potential for rapid action 
 lower cost compared to other methods 
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Disadvantages include: 
 potentially hazardous to applicator and environment 
 repeated exposure can lead to pest resistance 
 dependence requires annual costs 
 potential to cause harm to beneficial pests 
 potential to contaminate groundwater 
 potential adverse health effects from long term exposure to 
pesticides 
Other Antimicrobial Methods 
 
Rivera (2005) in his report “A review of chemical disinfection methods for minimally 
processed leafy vegetables” discussed chemical antimicrobial methods.  In his review of 
intervention strategies he discussed methods including ozone treatments, wash solutions, organic 
acid treatments, irradiation, and modified atmosphere packaging (MAP).  Other current methods 
in use for reduction of microorganisms in food include use of antioxidants in processed foods, 
and dehydration to reduce water activity. 
 
Chapter 4: Effectiveness of Bacteriophage on Foods 
 
 Bacteriophages exhibit beneficial effects when used on foods.  Research has been 
conducted to prove the effectiveness.  This chapter will discuss the benefits of bacteriophage as 
well as research in the area of bacteriophage effects when used on food products. 
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Benefits of Bacteriophages 
Bacteriophages can be applied directly to food and be eaten by the consumer with no 
harm to the properties of the food or to the human (USFDA-CFSAN 2006a).  Whereas sanitizers 
and pesticides typically consist of chemicals that are closely regulated by United States 
government under 21 CFR 178.1010 to prevent overuse and adulteration in foods (US 
Government Printing Office 2000).  Bacteriophages are specific for a particular pathogen, so 
phage could be selected based on the type of food and the environment to which the food was 
exposed.  For example, a phage specific for E. coli O157:H7 could be used on raw ground beef 
to ensure that mishandling or undercooking does not contribute to a human infection.  Listeria 
specific phage could be used on RTE foods after a lethality process and subsequent packaging 
where pathogens such as Salmonella and E. coli O157:H7 are not an issue.  Campylobacter and 
Salmonella specific phage (Figure 10) could be used on poultry products and possibly be adapted 
for use in milk products in the future.  The specificity of bacteriophage would decrease chances 
of bacterial mutations for resistance, as is common with non-specific sanitizers.  If bacteria 
mutate to resist the bacteriophage, the phage will in turn mutate to continue to infect the bacterial 
host.  Phage need their bacterial host to survive therefore mutation alongside the bacteria is 
crucial to the phage‟s existence. 
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Figure 10. Electron micrograph of a Salmonella 
phage isolated from the Inner Harbor in Baltimore,  
Maryland (K9514-5). 
(taken from USDA-ARS 2005) 
Research 
 Various experiments were conducted to determine effectiveness of phage use both 
preharvest and postharvest.  Preharvest measures in animals include experiments attempting to 
control or reduce Campylobacter in broiler chickens (Wagenaar et al. 2005).  Bacteriophages 69 
& 71 from the National Collection of Type Cultures (NCTC) in the UK were used in this 
experiment because they are both lytic for Campylobacter jejuni.  Results showed that treatment 
with phage reduced Campylobacter colonization in the broiler chickens to levels ten times lower 
than the control group, and no adverse side effects were noted in the chickens.  A significant 
decline occurred immediately after phage administration, but stabilized thereafter.  This could be 
a beneficial effect if used on broiler chickens just prior to slaughter, since rates of 
Campylobacter would possibly be at the lowest levels.  A study by Atterbury et al. (2005) 
showed a significant reduction in Campylobacter in broiler chickens when bacteriophage was 
present.  In fact, Campylobacter was undetectable in 71% of the phage-containing chickens. 
 Raya et al. (2006) discovered a phage, CEV1, in sheep that is effective against 17 of 19 
tested strains of E. coli O157:H7.  CEV1 is similar to phage T4, which was studied extensively 
and used safely in numerous applications for at least 50 years (Raya et al. 2006).  The new phage 
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could be used to treat sheep preharvest.  O‟Flynn et al. (2004) used a cocktail of three phages 
(e11/2, e4/1c, pp01) on meat to determine effectiveness against E. coli O157:H7.  The phages 
effectively lysed 12 of the 14 strains of E. coli O157:H7 against which they were tested. After 
contaminated meat was treated with the phage, 7 of the 9 samples had undetectable levels of  
E. coli O157:H7 (O‟Flynn et al. 2004).  The two remaining samples were at the low end of the 
threshold at <10 cfu/ml.  O‟Flynn et al. (2004) believe the phage cocktail could be useful as a 
control measure for E. coli O157:H7 during slaughter. 
 Research relating to company specific phage will be discussed in the next chapter. 
 
Chapter 5: Commercially Available Products 
 
Phage therapy in humans is a proven and common treatment for bacterial infections in 
areas of the world such as Russia.  Several companies throughout the United States and Europe 
are focusing research on use of phages as antimicrobials in food.  Some companies have 
government approvals on their products and are researching other product lines as well.  The 
companies conducting research and developing products for use on foods will be discussed in 
this chapter.  
Intralytix, Inc. 
 
Intralytix, Inc. is a phage research facility located in Baltimore, Maryland in the United 
States.  Intralytix, Inc. was founded in 1998 to “address growing problems in the control and 
treatment of disease-causing bacteria” (Intralytix 2006b).  Currently, their focus is on use of 
phage to enhance food safety, sanitation, and as therapy for bacterial diseases in humans and 
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animals.  LMP-102
TM
 is a phage preparation produced by Intralytix that targets Listeria 
monocytogenes, and consists of six bacteriophages that are found naturally occurring in the 
environment.  LMP-102
TM
 is manufactured using L. monocytogenes as the host, but the phages 
are later purified and no residue of the strain remains in the finished product.  LMP-102
TM
 is 
currently targeted for use on RTE products, and does not contain any preservatives or allergens.  
LMP-102
TM
 does not alter the taste, color, or odor of the meat product (Intralytix 2006c).  
According to Intralytix, Inc. (2006c) internal research, when used on foods contaminated with   
L. monocytogenes, LMP-102
 TM
 is effective in reducing the bacterial load 100-1000 fold.     
LMP-102
TM
 is also available for use on food processing equipment.  
ECP-100
 TM
 is a phage preparation similar to LMP-102
TM
 except that it targets E. coli 
O157:H7 (Intralytix 2006c).  ECP-100
 TM
 is currently in the final testing stages and Intralytix, 
Inc. predicts effective use on ground beef, fruits, and vegetables. 
Intralytix, Inc. has licensed phage preparations for veterinary use preharvest in animals 
intended for use in the human food chain.  Currently, they have three products licensed for use 
with poultry including SPLX-1
TM
 and PLSV-1
TM
 against Salmonella, and INT-401
TM
 against 
Clostridium perfringens (Intralytix 2006d).  Currently under development is a phage targeting  
E. coli O157:H7 for use in cattle preharvest. 
Phage SCPLX-1 contains four lytic phages specific for Salmonella Enteritidis.  Leverentz 
et al. (2001) studied the phage cocktail effectiveness on apples and honeydew melons. 
Salmonella was reduced as much as 3.5 logs on the honeydew melons, whereas no significant 
difference was observed between the control apples and the apples treated with phage. 
LMP-102
 TM
 has been tested on produce including red delicious apples and honeydew 
melons.  Leverentz et al. (2003) showed a significant decrease of L. monocytogenes on 
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honeydew melons when phage was applied, but minimal decrease on the apple slices.  In both 
the Salmonella and Listeria experiments, the researchers believed that the apple slices showed 
little to no reduction in target bacteria and decreased levels of phage titers due to the acidity of 
the apples (typical pH 4.2). 
 
EBI Food Safety 
 
EBI Food Safety is a phage research facility located in Wageningen, The Netherlands.  
EBI Food Safety‟s focus is on use of bacteriophage in foods, and one goal of the company is for 
use of bacteriophage as an antimicrobial to become a food industry standard (EBI Food Safety 
2006b).  Phage P100 was originally isolated from a wastewater sample taken from a dairy plant 
in Germany in 1997 (Carlton et al. 2005).  Listex
TM
 P-100 (Figure 11) is a phage preparation 
derived from Phage P100 that targets Listeria monocytogenes and a few other species of Listeria 
in foods without affecting flavor, taste, or odor.  EBI Food Safety (2006b) claims 100% 
effectiveness when Listex
TM
 P-100 is brought in contact with the host strain.  Listex
TM
 P-100 is 
cultivated using Listeria innocua as the host. 
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      Figure 11. Picture of a Listex
TM
 P100 product bottle. 
      (taken from EBI Food Safety 2006a) 
 
Carlton et al. (2005) conducted a study on P100 to determine the effectiveness against  
L. monocytogenes on food and its toxicity to animals.  The toxicity study was performed using 
rats, and the food of choice was surface-ripened red smear cheese also known as Muenster 
cheese.  The toxicity study consisted of a test group of ten rats given high doses (5 x 10
11
 pfu/ml) 
of P100 suspended in phosphate buffered saline orally for five days.  A control group of ten rats 
was given a placebo orally for five days.   Results of short-term phage use showed no evidence 
of changes in behavior, physical attributes, or signs of toxicity in the group given P100 (Carlton 
et al. 2005).  However, additional research is needed to determine long-term effects of toxicity 
related to phage use.   
The cheese used in the study was inoculated at a known level (2 x 10
1
 cfu/cm
2
) with L. 
monocytogenes, and subjected to either a repeated high dose or a low dose of P100, or a single 
high dose of the bacteriophage (Carlton et al. 2005).  According to this study, effects of P100 on 
the target bacteria were dose-dependent.  A repetitive low dose concentration of 1.5 x 10
8
 pfu/ml 
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obtained a 2-3 log decrease in the levels of Listeria.  When a repeated high dose concentration of 
3 x 10
9
 pfu/ml was used, results indicated absence of Listeria.  This was further confirmed by 
culturing the cheese using a selective enrichment and plating for Listeria, in which no presence 
of the target bacteria was found.  When a single high dose (6 x 10
8
 pfu/ml) was used, a uniform 
distribution of P100 was achieved on the surface of the cheese, and Listeria cells were 
undetectable (Figure 12). 
 
Figure 12. Graph showing Listex™ P100 can irradicate Listeria in cheese.  
The graph demonstrates recent results of successful eradication of Listeria in a cheese production 
environment. Day 0, Listeria monocytogenes inoculation 7 CFU/ cm
2
 cheese surface (taken from EBI Food 
Safety 2006a). 
 
The Chief Scientific Officer at EBI Food Safety, Dr. Steven Hagens, conducted a study 
on the effectiveness of Listex
TM
 P-100 on fish fillets and found that Listeria monocytogenes was 
drastically reduced (EBI Food Safety 2007a).  When used on fish fillets, EBI recommends 
dipping or spraying the fillets immediately following the filleting process. 
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Omnilytics, Inc. 
 
 Omnilytics, Inc. is a biotechnology company whose emphasis is on bacteriophage 
technology.  Locations include Salt Lake City, Utah, United States with an official presence in 
Honduras, Ecuador, and El Salvador.  One of their main focuses is the use of bacteriophage in 
agriculture settings such as on farm crops.  AgriPhage
TM
 is one of their products useful for 
controlling bacteria such as Xanthomonas campestris pv. vesicatoria and Pseudomonas syringae 
pv. tomato, among others that are known to cause bacterial spot and speck respectively in tomato 
and pepper plants.  The active ingredient in AgriPhage
TM 
is four billion phage per milliliter 
(Omnilytics 2004a).  AgriPhage
TM
 is meant to be used on farms at the preharvest level, and 
should be diluted prior to dispersal and applied using drip irrigation, ground or aerial spray 
equipment.  A unique service that Omnilytics provides growers is to periodically receive and 
analyze field samples and based on the results, they tailor the formulation for that grower and 
particular crop.   
 Omnilytics has two products that target bacteria on animal hides prior to slaughter.  Both 
products are termed BacWash
TM 
and target Salmonella and E. coli O157:H7 (Omnilytics 2007a, 
b).  BacWash
TM 
can be applied as a wash, mist, or spray directly to the live animal.  Future 
potential uses of the BacWash
TM 
line of products include treating animal holding areas, 
transportation equipment and containers, and living areas. 
Omnilytics has numerous other products under research in the areas of food and water, 
industrial, defense, pharmaceuticals, as well as a large variety of crops (Omnilytics 2004b).  The 
main food safety areas of research include E. coli O157:H7, Salmonella, Listeria, 
Campylobacter, and Pseudomonas aeruginosa for RTE foods, water, and processing facilities.  
Areas of research for crops include bacteria such as Burkholderia cepacia, and various strains of 
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Xanthomonas, Erwinia, and Clavibacter for use on common fruit and vegetable crops (Table 6).  
Importance from a food safety viewpoint exists because many of these crops are typically 
harvested and sold to consumers in raw form without further processing in many cases. Though 
many of the target bacteria are not necessarily pathogenic to humans, they are harmful to the 
crops and an outbreak can result in reduced crop yield and therefore drive up prices for 
consumers, as well as diminishing the quality of the available crops.  The potential exists to 
develop bacteriophage applications for use on crops against bacteria pathogenic to humans.  
Application in this area would be very beneficial as is evident from recent outbreaks of E. coli 
O157:H7 and Salmonella in fresh produce. 
 
Table 7. Chart of Omnilytics current areas of bacteriophage research in agriculture. 
 
Crop Pathogen Disease
Peach, Apricot, Cherry Xanthomonas campestris pv pruni Bacterial Leaf Spot
Citrus Xanthomonas campestris pv citrumelo Bacterial Leaf Streak
Citrus Xantomonas campestris pv citri Bacterial Canker
Walnut, Almond, Grape Agrobacterium tumefaciens Crown Gal
Walnut, Almond, Grape Xanthomonas campestris pv juglandis Walnut Blight
Apple, Pear Erwinia amylovora Fire Blight
Tomato Xanthomonas perforans Bacterial Leaf Spot
Pepper Xanthomonas euvesicatoria Bacterial Leaf Spot
Tomato Xanthomonas campestris pv vesicatoria Bacterial Leaf Spot
Strawberry Xanthamonas fragariae Angular Leaf Spot
Watermelon Acidovorax avenae subsp. Citrulli Fruit Blotch
Tomato Clavibacter michiganensis pv michiganensis Bacterial Canker
Onion Burkholderia cepacia Sour Skin and Bulb Rot
Lettuce Xanthomonas vitians Bacterial Leaf Spot
Cabbage Xanthomonas campestris pv campestris Blackrot
Potato Erwinia carotova Soft Rot
Snap Beans Xanthamonas campestris pv phaseoli Bacterial Blight
Cucumber, Squash, Pumpkins Pseudomonas syringae pv lachrymans Leaf Spot
Potato Clavibacter michiganensis pv sepedonicus Ring Rot
Geraniums Xanthomonas campestris pv pelargonii Bacterial Blight
Tobacco Ralstonia (Pseudomonas solanacearum) Bacterial Wilt  
Source: adapted from Omnilytics 2004b 
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Luna Innovations, Inc. 
 
 Luna Innovations has six facilities located throughout the state of Virginia in the United 
States.  Luna claims on their website to be currently working on bacteriophage solutions. Their 
work with food is in the research and development phase, as evidenced on the website 
http://www.lunainnovations.com/research/phages.htm and confirmed through email contact with 
an employee at the facility (Luna Innovations 2007). 
 
Chapter 6: Government Approvals 
 
United States and European government agencies have given approval or no objection to 
some of the phage products manufactured for use in foods and food products.  The approvals and 
special status given to bacteriophage products for use in foods are discussed in this chapter.  
 
United States Environmental Protection Agency 
 
Omnilytics obtained final rule for EPA registration of AgriPhage
TM 
product on December 
28, 2005 (Table 8).  A unique characteristic of this registration includes an exemption from the 
requirement of tolerance levels for the bacteriophage included in the product (USEPA 2005).  
The exemption means there is no maximum allowable level when using the product as a 
bactericide on tomato and pepper plants.  EPA is only allowed to provide this exemption if the 
product is deemed „safe.‟  According to Section 408(c)(2)(A)(ii) of the United States Federal 
Food, Drug, and Cosmetic Act (FFDCA) the definition of „safe‟ means “there is a reasonable 
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certainty that no harm will result from aggregate exposure to the pesticide chemical residue, 
including all anticipated dietary exposures and all other exposures for which there is reliable 
information” (US EPA 2005).  With this final rule, AgriPhageTM became the first phage-based 
product to be formally approved by any United States government regulatory agency. 
 
United States Food and Drug Administration  
 
On August 18, 2006 FDA announced approval of the use of bacteriophage as an 
antimicrobial food additive targeting Listeria monocytogenes on RTE meat and poultry products 
(USFDA CFSAN 2006a).  The approval was based on a petition regarding LMP-102
TM
 
submitted by Intralytix, Inc.  FDA based its approval of LMP-102
TM
 on review of several safety 
factors including L. monocytogenes residues remaining from manufacture of the product, 
potential human infection with phage, and lytic versus lysogenic phages.  FDA reviewed each of 
these areas with respect to LMP-102
TM
 and concluded that no potential residues exist, no 
potential for human infection exists, and the phages used in the cocktail are lytic, not lysogenic.  
Therefore, FDA concluded use of LMP-102
TM
 on RTE meat and poultry products is safe, when 
used at levels up to 1 ml/500 cm
2 
on the surface of a food product immediately prior to 
packaging (USFDA CFSAN 2006a).  Definitions of RTE meat products and control of Listeria 
monocytogenes on RTE meat products may be found in the Federal Code of Regulations in 
sections 9 CFR 430.1 and 430.4 respectively (GPO Access 2007). 
9 CFR 430.1 defines:  
“Antimicrobial agent. A substance in or added to an RTE product that has the effect of  
reducing or eliminating a microorganism, including a pathogen such as  
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L. monocytogenes, or that has the effect of suppressing or limiting growth of  
L. monocytogenes in the product throughout the shelf life of the product.”  
“Ready-to-eat (RTE) product. A meat or poultry product that is in a form that is edible  
without additional preparation to achieve food safety and may receive additional  
preparation for palatability or aesthetic, epicurean, gastronomic, or culinary purposes.  
RTE product is not required to bear a safe-handling instruction (as required for non-RTE  
products by 9 CFR 317.2(l) and 381.125(b)) or other labeling that directs that the product  
must be cooked or otherwise treated for safety, and can include frozen meat and poultry  
products.” 
 
9 CFR 430.4 specifies approved methods for controlling L. monocytogenes on RTE meat 
products (GPO Access 2007).  However, USDA-FSIS, not FDA, regulates the United States 
meat supply so this approval simply opens the door for USDA to approve LMP-102
TM
 for use on 
meat products. Until USDA evaluates and approves the product within its own agency, the 
product will not be permitted use on meat products under USDA inspection.  Once USDA 
approves LMP-102
TM
, users of the phage will be required to declare it as an ingredient on the 
label of the food product on which it was used. 
 On October 17, 2006 FDA approved Listex
TM
 P100, manufactured by EBI Food Safety, 
as Generally Recognized as Safe (GRAS).  The approval is based solely on EBI Food Safety‟s 
research and GRAS determination panel consisting of qualified and experienced scientists, and 
not based on FDA research (USFDA CFSAN 2006b).  The GRAS panel discussed issues 
pertaining to the identities of the phage and the target organism, the manufacturing process, 
specifications, approximate dietary intake when used on cheese, and studies concerning the 
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safety of the phage preparation.  The panel discussed research on potential pathogenicity, 
allergenicity, and virulence factors.  The GRAS panel concluded Listex
TM
 P-100 is GRAS when 
used as an antimicrobial on cheese at levels not exceeding 1 x 10
9
 pfu/gram.  EBI claims 
Listex
TM
 P-100 to be GRAS when used to control Listeria monocytogenes in cheeses that are 
typically aged and/or ripened such as Brie, Swiss, and Cheddar (USFDA CFSAN 2006b).  
According to EBI Food Safety (2007b), in July 2007 FDA extended GRAS status for Listex
TM
 P-
100 to cover all food products, not just cheese. 
 
United States Department of Agriculture 
 
 In 2007, USDA issued separate no objection letters for use of bacteriophage targeting 
Salmonella and E. coli O157:H7, also known as Omnilytic‟s BacWash product line, on animal 
hides prior to slaughter (Omnilytics 2007a,b).  These no objection letters open the door for 
livestock processors who wish to reduce the microbial load of the animals prior to slaughter.  
Use of BacWash targeting E. coli O157:H7 may reduce the number of positive samples on trim 
and save slaughter and processing facilities extra traceability paperwork that is required when 
selling or processing trim that is positive or presumptive for E. coli O157:H7. 
 
EU Law 
 
 In June 2007, The Public Inspection Authority of The Netherlands confirmed organic 
status of Listex
TM
 P-100 as organic according to EU Regulation (EEC) nr. 2092/91 Annex VI 
Section B (EBI Food Safety 2007c).  Therefore, Listex
TM
 P-100 is available for use in certified 
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organic products.  Article 14 (2) Regulation (EC) No 178/2002 defines unsafe foods and any 
product considered under this provision that is deemed unsafe or unfit for human consumption 
may not be placed on the market.  Therefore, according to EU Law bacteriophage may be 
allowed use on food products without prior authorization if adequate proof of safety is provided 
confirming it does not make the food unsafe (von Jagow and Teufer 2007).   
 
Table 8. Overview of phage approvals by government food regulatory agencies. 
Company Product Target Bacteria Approvals Date of Approval
Intralytix LMP-102 Listeria monocytogenes FDA 21 CFR Part 172 August 18, 2006
ECP-100 E.coli O157:H7 N/A N/A
EBI Food Safety Listex P-100 Listeria monocytogenes
FDA-GRAS GRN No. 000198; 
EU Law
October 17, 2006     
N/A
Omnilytics Agriphage
Xanthamonas campestris 
& Pseudomonas syringae EPA Reg. No. 67986-1 December 28, 2005
BacWash E. coli O157:H7 FSIS Case No. 06-NT-0239-N-A December 2006
BacWash Salmonella FSIS Case No. 07-NT-0253-N-A December 2006  
Chapter 7: Objections 
 
 A few consumer advocacy groups have filed objections to use of phage in food with 
government regulatory agencies or seek to warn consumers via their websites.  This chapter will 
discuss the objections and the reasoning behind the objections. 
 
Food and Water Watch 
 
 Food and Water Watch is a consumer advocacy group that aims for environmentally 
friendly practices and criticizes use of technologies deemed as risky or questionable when it 
comes to dealing with the public food and water supply.  On September 18, 2006 Food and 
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Water Watch submitted a formal objection to the provision allowing use of bacteriophages as a 
food additive.  Their main concern deals with the safety of the consumer during use of or after 
application of these new technological advances on food products.  Food and Water Watch 
(2006) does not feel that FDA sufficiently evaluated the potential risks.  Food and Water Watch 
(2006) based their objections on several factors: 
 FDA did not follow its own procedures for assessing safety when it 
comes to food additives 
 FDA relied on assumptions of safety when it came to evaluating 
residues of Listeriolysin O (LLO), one of L. monocytogenes 
virulence factors 
 Efficacy studies did not meet zero tolerance requirements set for 
Listeria monocytogenes in RTE foods 
 Research used to support FDA‟s decision was conducted by the 
company seeking product approval 
 FDA did not make the information regarding this rule available to 
the public, as noted when Food and Water Watch requested certain 
data  
 FDA failed to provide the required 30 day period for third parties to 
place objections to the rule  
Truth in Wellness 
 
 Truth in Wellness is an advocacy group devoted to providing consumers with accurate 
health information.  In an article titled “ The FDA Approves Viral Adulteration of Our Food 
Supply” Byron Richards (2006) of Truth in Wellness attacks the FDA approval of bacteriophage 
as a food additive.  Richards (2006) uses the more well-known, and often fear-invoking term 
“viruses” to discuss the phage in his article.  Richards warns the general public by asking, “ How 
do you like the idea of buying virus-infested food for your family?”   
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He accuses FDA of several atrocities including: 
 Adding more opportunity for adulteration to the food supply rather 
than addressing the problem of bacterial contamination at the source 
 Allowing a battle between two infectious organisms to fight each 
other in the human digestive tract 
 Not conducting adequate safety tests to ensure the long-term safety 
of use of phage as a food additive 
 Failing to prove without a doubt that the phage preparation will 
attack only the target organism and not mutate to recognize and 
attack human cells and other bacteria 
 Failing to satisfactorily address concerns over release of endotoxins 
when the phage causes the bacterial cell to lyse 
(Richards 2006) 
Richards (2006) encourages Americans to “boycott viral tainted foods” and “quit buying poor 
quality toxic food.”  
Other 
Capparelli et al. (2007) reported objections to use of phage as therapy in humans due to 
evidence of “rapid clearance in the spleen, an inability to kill intracellular bacteria, and 
stimulation of neutralizing antibodies.” 
 
Chapter 8: Conclusion 
 
Numerous reports of the safety of phage use in humans exist; specifically the 
effectiveness of phage therapy in humans over the past 80 years is very encouraging.  The fact 
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that bacteriophages only target specific bacterial organisms is a valid and proven justification for 
allowing phage preparations to come into contact with foods designated for human consumption.  
However the few doubts raised show the need for further research to prove the safety of phage 
use in foods beyond a reasonable doubt.   
If use of phage in RTE products becomes a widespread practice, consumers deserve to be 
notified that the products they are buying contain phage preparations as an additive since the use 
of any unknown substance in the food supply raises concern among consumers.  Therefore 
consumers should be educated on the issue of phage use so they can make an informed decision 
as to whether they want to consume food products treated with phage preparations.   
Use of phage at any phase of the food chain, from farm to fork, is not a substitute for 
sanitary conditions under any circumstance.  Government food regulatory agencies such as 
USDA and FDA should be required to ensure food companies continue to adhere to sanitary 
guidelines to prevent adulteration of the food supply and not rely solely on use of phage as a 
„quick fix.‟  Phages have the potential to be very effective in eliminating pathogenic bacteria on 
food products and in the future current research can be broadened to provide products targeting a 
greater range of bacterial pathogens. 
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